1-20 of 23861
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A new sUSPect in T-ALL risk stratification

Open Access
Stephanie J. Si Lim, David T. Teachey
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6467–6468.
https://doi.org/10.1182/bloodadvances.2025017870
Published: 2025
Journal Articles

Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma

Open Access
Maria Teresa Bilotta, Antonio Giovanni Solimando, Vanessa Desantis, Lucia Di Marzo, Andrea Sabatini, Sergio Forcelloni, Alessandro Andriano, Arcangelo Morizio, Antonella Argentiero, Roberto Ria, Linda Quatrini, Lorenzo Moretta, Paola Vacca, Nicola Tumino
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6246–6251.
https://doi.org/10.1182/bloodadvances.2025016659
Published: 2025
Includes: Supplemental data
Images
NK cells in MM progression. (A) The plot represents the percentages of NK cells (CD56+CD3–) among CD45+ cells expressed as median values ± standard error of the mean (SEM) in PB and BM of patients with MM among the different stages (MGUS, SMM, and NDMM). A Mann-Whitney t test was performed; ∗P < .05, ∗∗P < .005, and ∗∗∗P < .001. (B) Correlation between the percentage of total NK cells in BM of patients with MM (at different stages) and the percentage of plasma cells in the BM. Linear regression of correlation, Pearson r2 = 0.38. (C) Cytotoxic activity of NK cells isolated from PB of patients with MM (n = 3 MGUS = orange, n = 5 SMM = red, n = 3 NDMM = blue). NK cells from the PB of HD were used as control. Data are expressed as percentages of killed cells at different effector:target ratios. An unpaired t test was performed, comparing the values at the 10:1 ratio, ∗P < .05 and ∗∗P < .005. (D) MFI of NKp46 ± SEM expressed on total NK cells in PB and BM of patients with MM among the different stages (MGUS, SMM, and NDMM). A 2-way analysis of variance, Sidak multiple comparisons test was performed, ∗P < .05. (E) Dot plot of the 15 most distinguishing genes expressed in NK cells, stratified in the 3 stages of patients with MM (SMM, MGUS, and NDMM). Gene expression was analyzed using the 2-sided Wilcoxon rank-sum test with Bonferroni adjustment. Ribosomal genes and mitochondrial genes were removed for clarity. The color indicates the mean gene expression levels. (F) Dot plot of selected NK-cell genes encoding for inhibitory and activating receptors, stratified in the 3 stages of patients with MM (SMM, MGUS, and NDMM). The color indicates the mean gene expression levels. (G) Representative Sunburst view of the NK-cell subsets (green circle) among leukocytes (CD45+ cells, blue circle). NKdim (purple circle) and NKbright (light green circle) among the different MM stages in PB (left) and BM (right), analyzed with Cytobank Premium. (H) Percentages of NKdim (CD56dim) cells (among CD45+ cells) in PB and BM of patients with MM among the different stages. A Mann-Whitney t test was performed; ∗P < .05. (I) Correlation between the percentage of NKdim cells in the BM of patients with MM (at different stages) and the percentage of MM plasma cells (infiltrate). Linear regression of correlation, Pearson r2 = 0.52. (J) Frequency of total CD56+CD16– cells among total NK cells in PB and BM of patients with MM among the different stages. A Mann-Whitney t test was performed; ∗P < .05. (K) Frequency of CD56dimCD16– cells among NKdim cells in PB and BM of patients with MM among the different stages. A Mann-Whitney t test was performed; ∗P < .05. HD, healthy donor; MFI, mean fluorescence intensity.

NK cells in MM progression. (A) The plot represents the percentages of NK ...

Open Access
in Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma > Blood Advances
Published: 2025
Figure 1. NK cells in MM progression. (A) The plot represents the percentages of NK cells (CD56 + CD3 – ) among CD45 + cells expressed as median values ± standard error of the mean (SEM) in PB and BM of patients with MM among the different stages (MGUS, SMM, and NDMM). A Mann-Whitney t test w... More about this image found in NK cells in MM progression. (A) The plot represents the percentages of NK ...
Images
ILCs in MM progression. (A) Gating strategy for ILC identification and transcription factor expression in different ILC subsets present in BM and PB. (B) The plot represents the percentages of ILCs (Lin–/CD127+) expressed as median values ± SEM in PB and BM of patients with MM among the different stages (MGUS, SMM, and NDMM). (C) Representative Sunburst view of the ILC subsets among leukocytes (CD45+ cells, dark orange circle). Lin–CD127+ cells (orange circle), ILC1 (light orange), ILC2 (green), and ILC3 (light green) among the different MM stages in PB (left) and BM (right), analyzed with Cytobank Premium. (D-F) Frequency of ILC1 (D), ILC2 (E), and ILC2 CRTH2+CD117– (F) in PB and BM of patients with MM among the different stages. A Mann-Whitney t test was performed; ∗P < .05 and ∗∗P < .005.

ILCs in MM progression. (A) Gating strategy for ILC identification and tra...

Open Access
in Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma > Blood Advances
Published: 2025
Figure 2. ILCs in MM progression. (A) Gating strategy for ILC identification and transcription factor expression in different ILC subsets present in BM and PB. (B) The plot represents the percentages of ILCs (Lin – /CD127 + ) expressed as median values ± SEM in PB and BM of patients with MM amon... More about this image found in ILCs in MM progression. (A) Gating strategy for ILC identification and tra...
Journal Articles

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study

Open Access
Clinical Trials & Observations
Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant, Maya Hacini, Kamel Laribi, Sébastien Bailly, Thibaut Belmondo, Marie Maerevoet, Loic Ysebaert, Stéphanie Guidez, Steven Le Gouill, Christophe Bonnet, Marc André, Jehan Dupuis, Catherine Thieblemont, Emmanuel Bachy, Nicolas Daguindau, Franck Morschhauser, Sabine Tricot, Charline Moulin, Anne Banos, Roch Houot, Adrien Chauchet, Emmanuel Gyan, Guillaume Cartron, Hassan Farhat, Vincent Camus, Bernard Drenou, Hacene Zerazhi, David Sibon, Emmanuelle Nicolas-Virelizier, Caroline Delette, Sylvia Snauwaert, Sarah Bailly, Richard Delarue, Sylvain Carras, Albane Ledoux-Pilon, Marie-Cécile Parrens, Samuel Griolet, Philippe Gaulard, Marie-Hélène Delfau-Larue, Laurence de Leval, Gandhi Laurent Damaj
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6292–6304.
https://doi.org/10.1182/bloodadvances.2024015787
Published: 2025
Includes: Supplemental data
Journal Articles

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis

Open Access
Samira Glaeser-Khan, Satoko Ito, Manraj Sra, Rhys Richmond, Robert D. Bona, Harlan M. Krumholz, Stacy E. Croteau, Adam Cuker, George Goshua
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6237–6245.
https://doi.org/10.1182/bloodadvances.2025016822
Published: 2025
Includes: Supplemental data
Journal Articles

SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma

Open Access
Rudra Prasad Dutta, Heng-Huan Lee, Violetta V. Leshchenko, Ravi Prakash Shukla, Fangfang Yan, Yang Liu, H. Ümit Kaniskan, Xing Qiu, Jian Jin, Lapo Alinari, Michael Wang, Samir Parekh
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6267–6278.
https://doi.org/10.1182/bloodadvances.2025016801
Published: 2025
Includes: Supplemental data
Journal Articles

Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going

Open Access
Elena Zamagni, Marco Talarico
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6252–6266.
https://doi.org/10.1182/bloodadvances.2024015686
Published: 2025
Journal Articles

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras

Open Access
Clinical Trials & Observations
Yuting Yan, Bolin Yuan, Tonglu Qiu, Guoqiang Liu, Weihao Chen, Tingyu Wang, Ying Yu, Wenjie Xiong, Gang An, Dehui Zou, Jianyong Li, Liang Wang, Shuhua Yi
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6279–6291.
https://doi.org/10.1182/bloodadvances.2025017057
Published: 2025
Includes: Supplemental data
Journal Articles

Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies

Open Access
Michael Loschi, Marie-Charlotte Villy, Jacques-Emmanuel Galimard, Marie-Mathilde Auboiroux, Nathalie Gachard, Alexandre Perani, Matthieu Duchmann, Laetitia Largeaud, Stéphanie Nguyen, Flore Sicre de Fontbrune, Marie Robin, Ibrahim Yakoub-Agha, Etienne Daguindau, Sylvain Chantepie, Amandine Charbonnier, Delphine Lebon, Sébastien Maury, Hélène Labussiere-Wallet, Anne Huynh, Edouard Forcade, Cristina Castilla-Llorente, Thomas Cluzeau, Lionel Adès, Maud D’aveni, Raynier Devillier, Natacha Maillard, Sami Benachour, Hervé Dombret, Christian Récher, Arnaud Pigneux, Emmanuelle Clappier, Eric Delabesse, Nicolas Duployez, Pascal Turlure, Régis Peffault de Latour, Marie Sébert
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6314–6325.
https://doi.org/10.1182/bloodadvances.2025017084
Published: 2025
Includes: Supplemental data
Journal Articles

Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation

Open Access
Bhavna Bhasin-Chhabra, Tao Wang, John E. Levine, Shalini Shenoy, Miguel-Angel Perales, Asad Bashey, Hershel Raff, Wael Saber
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6394–6401.
https://doi.org/10.1182/bloodadvances.2025016655
Published: 2025
Includes: Supplemental data
Journal Articles

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL

Open Access
Malte Roerden, Luca Hensen, Britta Besemer, Friederike Schwartz, Kristina Reuss, Alisha Weiss-Haug, Lennart Harland, Franziska Ginsberg, Christoph Faul, Wolfgang Bethge, Claudia Lengerke
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6340–6344.
https://doi.org/10.1182/bloodadvances.2025017770
Published: 2025
Journal Articles

A novel isoform of tensin-1 promotes actin filament assembly for efficient erythroblast enucleation

Open Access
Arit Ghosh, Megan Coffin, Dimitri M. Diaz, Sarah Barndt, Vincent P. Schulz, Patrick G. Gallagher, Su Hao Lo, Velia M. Fowler
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6356–6369.
https://doi.org/10.1182/bloodadvances.2025016100
Published: 2025
Includes: Supplemental data
Journal Articles

Emicizumab in infants: not just cost-effective but mandatory

Open Access
Guy Young
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6354–6355.
https://doi.org/10.1182/bloodadvances.2025017871
Published: 2025
Images
Disease patterns by 18F-FDG–PET/CT and WB-DW-MRI. (A) DD by 18F-FDG–PET/CT; (B) DD by WB-DW-MRI; (C) focal on DD by 18F-FDG–PET/CT; (D) focal on DD by WB-DW-MRI; (E) micronodular disease by WB-DW-MRI; (F) focal disease by 18F-FDG–PET/CT before (i) and after (ii) treatment; (G-H) focal disease by WB-DW-MRI before (i) and after (ii) treatment; (I) PSD by 18F-FDG–PET/CT (coronal, i; axial, ii); (J) PSD by WB-DW-MRI (coronal, i; axial, ii); (K) EMD by 18F-FDG–PET/CT (coronal, i; axial, ii); and (L) EMD by WB-DW-MRI (coronal, i; axial, ii).

Disease patterns by 18 F-FDG–PET/CT and WB-DW-MRI. (A) DD by 18 F-FDG–PE...

Open Access
in Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going > Blood Advances
Published: 2025
Figure 1. Disease patterns by 18 F-FDG–PET/CT and WB-DW-MRI. (A) DD by 18 F-FDG–PET/CT; (B) DD by WB-DW-MRI; (C) focal on DD by 18 F-FDG–PET/CT; (D) focal on DD by WB-DW-MRI; (E) micronodular disease by WB-DW-MRI; (F) focal disease by 18 F-FDG–PET/CT before (i) and after (ii) treatment; (G-H... More about this image found in Disease patterns by 18 F-FDG–PET/CT and WB-DW-MRI. (A) DD by 18 F-FDG–PE...
Images
Relation between ADC values, signal intensity in DWI sequences, and BM cellular density during disease course and response to therapy. MGUS, monoclonal gammopathy of undetermined significance. Adapted from Dutoit et al92 and Ormond et al.93

Relation between ADC values, signal intensity in DWI sequences, and BM cell...

Open Access
in Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going > Blood Advances
Published: 2025
Figure 2. Relation between ADC values, signal intensity in DWI sequences, and BM cellular density during disease course and response to therapy. MGUS, monoclonal gammopathy of undetermined significance. Adapted from Dutoit et al 92 and Ormond et al. 93 More about this image found in Relation between ADC values, signal intensity in DWI sequences, and BM cell...
Images
The distribution of MG in CLL and its relationship to IGHV gene. (A) Distribution of different subtypes of MG. (B) The distribution of lambda and kappa light-chain use in different types of paraproteinemia. (C) Proportion of patients with mutated IGHV in different MG group. (D) Relationship between MG subtypes and IGHV mutational status. (E) The distribution of IGHV segment use in patients with or without MG.

The distribution of MG in CLL and its relationship to IGHV gene. (A) Dis...

Open Access
in Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras > Blood Advances
Published: 2025
Figure 1. The distribution of MG in CLL and its relationship to IGHV gene. (A) Distribution of different subtypes of MG. (B) The distribution of lambda and kappa light-chain use in different types of paraproteinemia. (C) Proportion of patients with mutated IGHV in different MG group. (D) Rel... More about this image found in The distribution of MG in CLL and its relationship to IGHV gene. (A) Dis...
Images
Gene mutation spectrum detected by next-generation target sequencing. (A) Gene mutation rate in MG-positive and MG-negative patients with CLL. (B) Mutation rates in patients with different types of paraproteinemia. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.

Gene mutation spectrum detected by next-generation target sequencing. (A) ...

Open Access
in Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras > Blood Advances
Published: 2025
Figure 2. Gene mutation spectrum detected by next-generation target sequencing. (A) Gene mutation rate in MG-positive and MG-negative patients with CLL. (B) Mutation rates in patients with different types of paraproteinemia. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. More about this image found in Gene mutation spectrum detected by next-generation target sequencing. (A) ...
Images
Survival analysis of MG-positive and MG-negative patients with CLL. (A) TTFT. (B) PFS. (C) OS. ∗P &lt; .05; ∗∗P &lt; .01; ∗∗∗P &lt; .001.

Survival analysis of MG-positive and MG-negative patients with CLL. (A) TT...

Open Access
in Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras > Blood Advances
Published: 2025
Figure 3. Survival analysis of MG-positive and MG-negative patients with CLL. (A) TTFT. (B) PFS. (C) OS. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. More about this image found in Survival analysis of MG-positive and MG-negative patients with CLL. (A) TT...
Images
Subgroup survival analysis of patients with MG stratified by IGHV mutation status. (A) The proportion of patients with MG in each risk group of CLL-IPI. (B-C) PFS and OS in patients with CLL with mutated IGHV. (D-E) PFS and OS in patients with CLL with unmutated IGHV.

Subgroup survival analysis of patients with MG stratified by IGHV mutatio...

Open Access
in Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras > Blood Advances
Published: 2025
Figure 4. Subgroup survival analysis of patients with MG stratified by IGHV mutation status. (A) The proportion of patients with MG in each risk group of CLL-IPI. (B-C) PFS and OS in patients with CLL with mutated IGHV . (D-E) PFS and OS in patients with CLL with unmutated IGHV . More about this image found in Subgroup survival analysis of patients with MG stratified by IGHV mutatio...